on SARTORIUS STED BIO (EPA:DIM)
Sartorius Stedim Biotech First Quarter 2025 Results
Sartorius Stedim Biotech reported sales of €745 million for the first quarter of 2025. This performance represents an increase of 10.4% at constant exchange rates. Demand for biomanufacturing consumables was strong, while equipment investments remained moderate. The book-to-bill ratio remained above 1.
Current EBITDA profit amounted to €229 million, a significant increase compared to the previous year, bringing the EBITDA margin to 30.8%. Current net profit increased by 34.5% to €113 million.
Management expects revenue growth of approximately 7% by 2025, with a projected EBITDA margin of between 30% and 31%. These forecasts are subject to market volatility and potential pricing measures.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all SARTORIUS STED BIO news